Stage 1
Current page problem
The current page leaves important purchase questions unanswered.
- NDC and package size
- Route and dosage form
- Rx-only and compliance status
- Unused and in-use storage details
Product page improvement
A stronger regulated catalog page should keep identity, strength, package, storage, identifiers, and compliance guardrails clear without adding medical advice.
Start with the available product information, fill the buyer gaps, then write the page.
Stage 1
The current page leaves important purchase questions unanswered.
Stage 2
Useful details are grouped before the customer-facing copy is written.
Stage 3
The improved page gives shoppers clearer answers and store teams cleaner fields.
Sparse product information becomes useful buyer guidance: what the product does, who it fits, what to check, and which details matter before purchase.
The weak record names the medication and a strength, but it does not separate the brand, generic name, NDC, package, route, dosage form, storage rules, labeler, or compliance requirements.
The full buyer-facing page draft appears below.
Buyer details are added from approved label information so the catalog page separates package, identity, storage, and compliance details for pharmacy and health-system buyers.
5 drug identity details checked for the page, product file, and marketplace fields.
5 strength and package details checked for the page, product file, and marketplace fields.
4 storage and handling details checked for the page, product file, and marketplace fields.
4 compliance guardrails details checked for the page, product file, and marketplace fields.
The buyer details turn a thin item row into clearer shopper answers, cleaner attributes, and product-page sections that are easier to use across stores and marketplaces.
| Field group | Current gap | Buyer detail added | Why it matters |
|---|---|---|---|
| Drug identity | LANTUS PEN | Brand, generic name, dosage form, route, prescription status, and labeler separated | A regulated product record that is easier for pharmacy buyers and catalog teams to understand |
| Package and identifiers | 3 mL pen | NDC 0088-2219-05, five 3 mL SoloStar prefilled pens per carton, needles not included | Cleaner product file and catalog fields for the exact sellable package |
| Strength | 100 units/mL | Strength normalized as insulin glargine 100 units/mL (U-100) | Less ambiguity between brand, generic name, concentration, dosage form, and package |
| Storage and handling | Keep cold | Unused refrigeration range, do-not-freeze handling, heat/light protection, and in-use timing | Important handling details are separated instead of buried in a short note |
Your store page stays buyer-facing. Marketplace outputs are separate field packages for Amazon and Walmart, prepared for destination rules, validation checks, and merchant-controlled values.
Keep NDC, package, storage, Rx status, and compliance gates separate before any marketplace decision.
Prepare regulated product fields only after pharmacy, legal, and seller-program requirements are confirmed.
This LANTUS SoloStar record separates brand, generic name, strength, dosage form, route, NDC, package size, storage, manufacturer, and Rx-only status for pharmacy catalog review.
| Item Number | NDC 0088-2219-05 |
|---|---|
| Unit | Carton of 5 prefilled pens |
Prescription-drug catalog pages need a different standard than ordinary online store pages. The job is not to invent benefits, dosing, switching, substitution, or treatment claims. The job is to keep label-backed identity, package, storage, and compliance fields clear for qualified buyers and required approvals.
For LANTUS SoloStar, the record keeps brand display, generic name, NDC, route, dosage form, package, strength, storage handling, manufacturer, and compliance status in separate fields.
No. This is a catalog-clarity page only. The approved drug label and qualified clinical or pharmacy approval remain required for prescription-drug information.
The NDC helps identify the exact package. In this example, NDC 0088-2219-05 maps to the five-pen LANTUS SoloStar carton.
The record separates unused refrigeration, do-not-freeze handling, heat and light protection, and in-use timing so the details can be checked against the approved label.
Dosing, substitution, clinical, and regulatory language must come from approved sources and be approved by qualified people before publishing.
| Brand Display | LANTUS SoloStar |
|---|---|
| Generic Name | insulin glargine |
| Manufacturer/Labeler | sanofi-aventis U.S. LLC |
| Product Type | Human prescription drug |
| Prescription Status | Rx only |
| Dosage Form | Injection, solution |
| Route | Subcutaneous |
| Strength | 100 units/mL (U-100) |
| Package NDC | 0088-2219-05 |
| Package | 5 single-patient-use 3 mL SoloStar prefilled pens per carton |
| Needles | Not included |
| Unused Storage | Refrigerate at 36°F to 46°F (2°C to 8°C); do not freeze |
| Handling | Protect from direct heat and light |
| In-Use Timing | Use within 28 days after initial use |
| Compliance Gate | Pharmacist or regulatory approval before publishing |
| Blocked Copy | No dosing, switching, substitution, treatment, or medical-advice claims |
Compare this draft with the example library, the product overview, or the demo path.
Request a demo to review the agency path, merchant product-page path, or store-update path that fits your team.